Why Science? | PRIDE Archive Proteomics Projects and File Evidence

Proteomics asks which proteins and peptides are present, how confidently they were identified and how their abundance may differ. PRIDE Archive preserves public mass-spectrometry proteomics datasets so the paper, project, sample description, raw spectra and result files can be inspected together.

A public project is not automatically an analysis-ready package or an independently verified conclusion. Reuse begins by identifying the PXD project, rebuilding the experimental design and deciding what each file represents. This guide makes that evidence chain readable for science students and early bioinformatics learners.

Keep a project card, sample table and file manifest beside the archive page. Every graph should trace backward through a result file and raw acquisition to a named sample and study factor. That route matters more than the number of gigabytes downloaded.

Start with a question narrow enough to audit. A useful classroom investigation may ask whether a small set of reported proteins differs between two documented conditions, or whether one identification can be followed from spectrum to peptide and protein group. Define the comparison before choosing files.

Estimate storage and computation from the manifest rather than clicking every download link. Raw vendor data can be large, while supplied identification tables may support an introductory exercise. Choosing processed data is acceptable when the limitation is explicit and the project does not claim to have reprocessed spectra.

Protect the archive state. Keep downloaded files read-only, compute hashes where possible and place conversions or filtered tables in a separate derived directory. A reproducible folder has a source manifest, processing log and results directory, not one mixed collection of renamed files.

Protein inference creates another important boundary. Peptides can map to more than one protein, and software may report protein groups rather than uniquely demonstrated individual proteins. Preserve the grouping and evidence fields instead of turning every accession into an independent identification.

Quantification also needs method context. Label-free intensities, reporter-ion values and targeted measurements follow different workflows and assumptions. Record missing-value handling, normalisation and aggregation before comparing abundance. A colourful fold change does not explain how the number was produced.

Controls belong in the sample map. Blanks, standards, pooled references and quality-control injections can diagnose contamination or drift but are not ordinary biological replicates. Keep them visible and explain their analytical role before excluding them from the main comparison.

When software produces a long report, choose fields because they answer the question. Define score, confidence, peptide count, protein group and quantitative column using the format or tool documentation. Unlabelled filtering can make a result look cleaner while removing the evidence needed to evaluate it.

The linked article remains important. Repository metadata provides structure and files, while the paper explains sample preparation, experimental decisions and interpretation. Compare the two and record inconsistencies; neither should silently overwrite the other.

A final review should follow one result in both directions. From the biological claim, find the reported protein, peptide or quantitative row and the contributing files. From one raw file, recover the sample, factor and downstream result. Agreement shows the evidence chain is intact.

Before statistical analysis, create a design matrix whose rows are biological samples and whose columns are factors and covariates. Join measurements through stable sample or assay identifiers, then require every included data column to match exactly once. Extra, missing or duplicated joins should stop the workflow.

Record exclusions before looking for the desired pattern. A failed acquisition, contaminant-dominated run or incomplete metadata row may justify exclusion, but the reason and affected accession must remain visible. Sensitivity analysis can show whether a conclusion depends on one disputed decision.

Contaminant and decoy entries need explicit handling. Search databases often include common contaminants and reversed or shuffled sequences for error estimation. Preserve their labels during quality control and state whether they were removed before biological interpretation.

Post-translational modifications add another layer of uncertainty. A peptide can support the presence of a modification without localising it uniquely to one residue. Keep site-probability or localisation evidence and avoid converting a modified peptide into a definitive protein-site claim.

Protein identifiers can change between sequence-database releases, and several accessions can describe related isoforms or groups. Save the exact database version used by the submitter or reanalysis and map identifiers only through a documented rule. The familiar gene symbol is useful for reading but insufficient for provenance.

For quantitative comparisons, show individual biological samples and uncertainty rather than only a fold-change ranking. State whether missing values were filtered or imputed and whether multiple-testing correction was applied. Statistical significance does not establish biological mechanism, while a large fold change without reliable measurement remains uncertain.

Visual quality-control plots should answer named questions: do runs cluster by biology or batch, are intensities comparable, and do controls behave as expected? A polished principal-component plot is not proof of success unless axes, included samples and preprocessing are documented.

If raw reanalysis is beyond the project's computing resources, scope the work to metadata and submitted results. That is still authentic science when the limitation is explicit. Reproducibility means another reader can repeat the chosen route, not that every learner must rebuild the entire proteomics pipeline.

At publication time, include the file manifest or a machine-readable supplement where practical. A prose methods paragraph cannot list every selected raw and result object as precisely as an accession table can. The supplement lets future readers update software while preserving the same inputs.

Check units before comparing quantitative columns. Intensities, ratios and normalised values may all be numeric but describe different scales. Preserve the submitter's column definition and create a new field for any derived transformation.

Fractions require special counting. Several raw files can represent complementary fractions from the same preparation rather than independent observations. Aggregate only with a method suited to the experiment, and retain the fraction-to-sample map.

Targeted experiments may include transition lists and scheduled windows that define what was measured. Absence of a peptide outside that target list is not evidence of biological absence. Record assay scope beside every negative conclusion.

Data-independent acquisition and discovery workflows can also produce very different evidence structures. Identify the acquisition and analysis route rather than assuming every proteomics project centres on the same kind of peptide-spectrum match.

Keep software logs with the results. Warning messages, database counts and version strings often explain unexpected output. A successful exit code cannot prove that parameters or reference files were the intended ones.

When comparing projects, harmonise identifiers, factors and processing before comparing abundance. Differences between repositories or studies may reflect design and software as much as biology. Preserve each project's original evidence before building a shared table.

End with a claim ledger listing statement, supporting project, sample set, files, analysis and limitation. This compact object makes fact-checking faster and discourages a strong conclusion from floating free of its spectra and metadata.

Read peptide sequences with modifications and charge states intact. Collapsing them too early can merge distinct evidence, while treating every charge state as a new biological peptide can inflate counts. Define the unit before summarising.

Where spectral libraries or predicted libraries are used, record their source and version. Library choice affects which signals can be identified and quantified, so it belongs in the evidence trail beside the raw acquisition and search parameters.

These checks make the final story simpler: named samples produced named files, documented software produced reported results, and the conclusion stays within that chain.

Before analysis, save the PXD accession, project title, submitter, release status, publication, organism, instrument, sample metadata file and a complete file manifest. Then state which raw, identification and quantification files you actually inspected.

Finish with an audit count: expected samples, assays, raw files, result files, downloaded files and unmatched items. Proteomics pipelines can run on an incomplete bundle, so arithmetic is part of evidence quality.

Reading object	What it can support	Question to keep visible
PXD project	Dataset identity, summary, submitter and publication context	Is this the intended public project and version?
Sample metadata	Biological source, factors and assay relationships	Can every analysed file be traced to a sample?
Raw spectrum file	Instrument output before identification or quantification	Which acquisition and file format does it represent?
Result file	Reported identifications or quantitative outputs	Which software, database and thresholds produced it?

Sources and next reading

Substantive resource claims in this article were checked against the primary pages below. A database record is a structured route into evidence; it does not by itself prove a new biological conclusion. Recheck the live record, evidence labels and release context before using it in assessed work or research.

Primary sources

• PRIDE Archive home and scope — accessed 24 October 2026.
• PRIDE Archive documentation — accessed 24 October 2026.
• PRIDE data annotation system — accessed 24 October 2026.
• PRIDE links to other omics data — accessed 24 October 2026.
• PRIDE licence — accessed 24 October 2026.

Continue through eduKate

• ProteomeXchange and public proteomics data
• SDRF-Proteomics and sample metadata
• mzIdentML and proteomics identification results
• Science Learning Hub
• Education Hub
• Careers by Subject and Capability